(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
20 August 2020 (20.08.2020)

WIPO | PCT

(10) International Publication Number
WO 2020/168178 A1

(51) International Patent Classification:
A61K 31/519 (2006.01) *A61K 31/5386* (2006.01)
A61K 31/5377 (2006.01) *A61P 35/00* (2006.01)

(21) International Application Number:
PCT/US2020/018271

(22) International Filing Date:
14 February 2020 (14.02.2020)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
62/806,265 15 February 2019 (15.02.2019) US

(71) Applicant: **INCYTE CORPORATION** [US/US]; 1801 Augustine Cut-Off, Wilmington, Delaware 19803 (US).

(72) Inventor; and
(71) Applicant: **WINTERTON, Sarah** [US/US]; 1801 Augustine Cut-Off, Wilmington, Delaware 19803 (US).

(72) Inventors: **YE, Min**; 1801 Augustine Cut-Off, Wilmington, Delaware 19803 (US). **CHEN, Yingnan**; 1801 Augustine Cut-Off, Wilmington, Delaware 19803 (US). **FAVATA, Margaret**; 1801 Augustine Cut-Off, Wilmington, Delaware 19803 (US). **LO, Yvonne**; 1801 Augustine Cut-Off, Wilmington, Delaware 19803 (US). **SOKOLSKY, Alexander**; 1801 Augustine Cut-Off, Wilmington, Delaware 19803 (US). **WU, Liangxing**; 1801 Augustine Cut-Off, Wilmington, Delaware 19803 (US). **YAO, Wenqing**; 1801 Augustine Cut-Off, Wilmington, Delaware 19803 (US).

(74) Agent: **BRENNAN, Jack**; Fish & Richardson P.C., P.O. Box 1022, Minneapolis, Minnesota 55440-1022 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report (Art. 21(3))*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
— *with sequence listing part of description (Rule 5.2(a))*

(54) **Title:** CYCLIN-DEPENDENT KINASE 2 BIOMARKERS AND USES THEREOF

(57) **Abstract:** Biomarkers are provided that are predictive and/or indicative of a subject's responsiveness to a cyclin-dependent kinase 2 (CDK2) inhibitor. The biomarkers, compositions, and methods described herein are useful in selecting appropriate treatment modalities for a subject having, suspected of having, or at risk of developing a disease or disorder associated with CDK2 and for monitoring treatment.

WO 2020/168178 A1